You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

CLINICAL TRIALS PROFILE FOR ICLUSIG


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Iclusig

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00660920 ↗ Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies Completed Ariad Pharmaceuticals Phase 1 2008-06-01 The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.
NCT01207440 ↗ Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Completed Ariad Pharmaceuticals Phase 2 2010-09-30 The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the (T)hreonine-315-(I)soleucine (T315I) mutation.
NCT01424982 ↗ Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia Recruiting Ariad Pharmaceuticals Phase 2 2011-10-05 This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib hydrochloride may be an effective treatment for acute lymphoblastic leukemia.
NCT01424982 ↗ Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia Recruiting M.D. Anderson Cancer Center Phase 2 2011-10-05 This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib hydrochloride may be an effective treatment for acute lymphoblastic leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iclusig

Condition Name

Condition Name for Iclusig
Intervention Trials
Acute Lymphoblastic Leukemia 6
Recurrent Acute Lymphoblastic Leukemia 4
Leukemia 4
Refractory Acute Lymphoblastic Leukemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Iclusig
Intervention Trials
Leukemia 19
Leukemia, Myeloid 16
Precursor Cell Lymphoblastic Leukemia-Lymphoma 12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Iclusig

Trials by Country

Trials by Country for Iclusig
Location Trials
United States 95
France 19
China 18
Japan 12
Poland 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Iclusig
Location Trials
Texas 12
Oregon 8
Maryland 5
Michigan 5
California 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Iclusig

Clinical Trial Phase

Clinical Trial Phase for Iclusig
Clinical Trial Phase Trials
Phase 3 3
Phase 2 18
Phase 1/Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Iclusig
Clinical Trial Phase Trials
Recruiting 12
Completed 6
Withdrawn 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Iclusig

Sponsor Name

Sponsor Name for Iclusig
Sponsor Trials
Ariad Pharmaceuticals 11
National Cancer Institute (NCI) 7
M.D. Anderson Cancer Center 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Iclusig
Sponsor Trials
Other 19
Industry 19
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.